Complete Genomics (GNOM -16%) drops hard after missing on its Q1 late yesterday on wider-than-expected losses. Revenue was down 42% Y/Y, largely due to an unexpected revenue recognition deferral for 200 units previously sold into Q2.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs